Key points are not available for this paper at this time.
We conservatively estimated the US economic burden of fungal diseases as 11. 5 billion in 2019: direct medical costs (7. 5 billion), productivity loss due to absenteeism (870 million), and premature deaths (3. 2 billion). An alternative "value of statistical life" approach yielded >48 billion. These are likely underestimates given underdiagnosis and underreporting.
Benedict et al. (Wed,) studied this question.